Clinical Trial Detail

NCT ID NCT02883049
Title Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

B-lymphoblastic leukemia/lymphoma

Therapies

Dasatinib

Dexamethasone + Doxorubicin

Prednisone

Vincristine Sulfate

Thioguanine

Cytarabine

Mercaptopurine

Leucovorin

Methotrexate

Pegaspargase

Etoposide

Clofarabine

Age Groups: adult child

No variant requirements are available.